The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Allegra Orthopaedics (AMT) has started distributing Australian made and designed face shields to front line workers
  • The company has already received 105,000 face shield orders and is in discussions with major hospital groups who are interested in the product
  • Healthcare workers rely on equipment and uniforms to protect themselves against COVID-19
  • Allegra says it is monitoring its expenditure during these challenging times
  • The face shields are expected to give the company some extra cash in the hand
  • Allegra is down 23.1 per cent on the market today, trading for 15¢ apiece

Allegra Orthopaedics (AMT) has started distributing Australian made and designed face shields to front line workers.

The company has already received 105,000 face shield orders and is in discussions with major hospital groups who are interested in the product.

These face shields have been approved by the Therapeutic Goods Administration (TGA).

Allegra says it is monitoring its expenditure during these challenging times. The face shields are expected to give the company some extra cash in the hand as the Federal Government suspended all elective surgeries in public and private hospitals.

CEO Jenny Swain is proud to supply Australian designed and manufactured face shields to the front line carers.

“The current demand for PPE Illustrates the need for companies to be ready to diversify during this global uncertainty surrounding COVID-19,” she said.

“I am pleased to say that Allegra has been proactive in making this happen and more importantly, we are supporting Australian manufacturing,” she added.

Allegra is down 23.1 per cent on the market today, trading for 15¢ apiece at 1:54 pm AEST.

AMT by the numbers
More From The Market Online

Inoviq closes the gap on blood test results for ovarian cancer

INOVIQ has announced encouraging blood test identification results for ovarian cancer – cancer-positive tests saw a…

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to…

Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at

Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine Nasal Spray, in the…